AstraZeneca makes another vaccine supply agreement

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Daniel Chetroni)
(Image: Getty/Daniel Chetroni)

Related tags: Astrazeneca, Symbiosis, COVID-19, Coronavirus

AZ enters a supply agreement with Symbiosis as it continues to work on bolstering supply for its COVID-19 vaccine.

Symbiosis announced that it had reached a deal with AstraZeneca to provide ‘fast-track’ access to sterile vaccine drug product manufacturing capacity.

The contract manufacturing organization (CMO) will become one of the small army of partners that AZ has amassed to build the capacity required to develop and commercialize a potential vaccine against COVID-19.

Early in June, AZ revealed that it had hit capacity to produce two billion doses​ of AZD1222 by 2021, through a number a partnerships with the Coalition for Epidemic Preparedness Innovations, Gavi, and the Serum Institute of India, among others.

Recently, AZ also reached an agreement with Catalent​ for the latter company to provide vial filling and packaging services once the vaccine candidate reaches commercialization.

The latest deal with Symbiosis will see the CMO provide sterile manufacturing of the vaccine for clinical trials, with Phase II/III trials ongoing at multiple site across the UK and readouts from these expected in August or September.

Colin MacKay, CEO of Symbiosis, said, “With many years of direct experience manufacturing medicines and vaccines of this nature for clinical trials and commercial markets, we are delighted to be able to leverage our expertise and competitive strengths to accelerate the development of this vaccine for AZ and to add value to the project.”

Earlier this year, the Sterling-based CMO had expanded its site​ to add additional manufacturing services and temperature-controlled storage.

Symbiosis StIrling, Scotland
Symbiosis' Stirling site. Image: Symbiosis

The development was part-funded by the UK government, which was provided specifically to improve the supply of viral vectors.

The funding decision has paid dividends for the UK-based vaccine, which the national government has already moved to reserve priority supply​ on, with an order of 30 million doses.

Symbiosis has also benefited from the increased demand for viral vectors, nearly doubling its employee count since the beginning of the year, as it now counts 100 staff part of its team – up from 60 at the time of the expansion.

Related news

Show more

Related products

show more

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Blazar™ Platform: Rodent Virus Panel

Blazar™ Platform: Rodent Virus Panel

Viral Safety for mAb: Prevent, Detect, Remove | 16-Nov-2020 | Technical / White Paper

We have a long history of developing innovative molecular technologies for cell line characterization and lot release testing for the biopharmaceutical...

Monitoring SARS-CoV-2 interaction with ACE2

Monitoring SARS-CoV-2 interaction with ACE2

Take the Right Path Upstream with MilliporeSigma | 02-Nov-2020 | Technical / White Paper

In this technical note, we investigate the interactions between the following: The spike glycoprotein binding with ACE2, Spike glycoprotein and anti-spike...

Related suppliers

Follow us

Products

View more

Webinars